Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 87% above its 4-year average of 0.00, around the middle of its 4-year range (0.00–0.00).
As of the fiscal period ended Tuesday, June 30, 2026. 66.61% above its 12-month average of 0.00.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+66.61%
CURRENT VS 3Y AVG
+45.11%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 574 covered companies
CURRENT VS SECTOR MEDIAN
-99.26%
vs the sector median at left
ArriVent BioPharma, Inc.
Market Cap
$622.01M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$609.24M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.06
5Y Avg
0.06
Market Cap
$642.86M
Debt to Equity Ratio
0.05
TTM Avg
0.13
3Y Avg
0.11
5Y Avg
0.08
Market Cap
$600.51M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$600.01M
Debt to Equity Ratio
N/A
TTM Avg
0.72
3Y Avg
2.89
5Y Avg
12.33
Market Cap
$585.62M
Debt to Equity Ratio
0.27
TTM Avg
0.26
3Y Avg
0.14
5Y Avg
0.13
Market Cap
$666.04M
Debt to Equity Ratio
0.01
TTM Avg
0.11
3Y Avg
0.32
5Y Avg
0.40
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $622.01M | 0.00 | 0.00 | 0.00 | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $609.24M | 0.00 | 0.03 | 0.06 | 0.06 |
| Climb Bio, Inc. (CLYM)vs › | $637.30M | 0.01 | 0.00 | 0.00 | 0.00 |
| OmniAb, Inc. (OABI)vs › | $647.30M | 0.07 | 0.08 | 0.08 | 0.07 |
| Aura Biosciences, Inc. (AURA)vs › | $642.86M | 0.05 | 0.13 | 0.11 | 0.08 |
| Fulgent Genetics, Inc. (FLGT)vs › | $600.51M | 0.01 | 0.01 | 0.02 | 0.02 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.01M | N/A | 0.72 | 2.89 | 12.33 |
| OrthoPediatrics Corp. (KIDS)vs › | $585.62M | 0.27 | 0.26 | 0.14 | 0.13 |
| MiMedx Group, Inc. (MDXG)vs › | $666.04M | 0.01 | 0.11 | 0.32 | 0.40 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $673.11M | 0.10 | 0.04 | 0.05 | 0.04 |
Debt/Equity
0.00
Current Ratio
14.16
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
